Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 20, 2022 in Diabetes mellitus | 0 comments

In a nutshell

This study evaluated the antibody response and side effects associated with COVID-19 vaccines administration in patients with type 1 (T1D) and type 2 diabetes (T2D), people without diabetes. The data showed similar immune responses in patients with and without diabetes after the second COVID-19 vaccine, regardless of glucose control.

Some background

Patients with severe or fatal Coronavirus Disease (COVID-19) that have become hospitalized, frequently have other underlying conditions such as diabetes. COVID-19 vaccination is highly recommended and prioritized in patients with diabetes, as a result. Patients with diabetes have a compromised immune response to SARS-CoV-2, the virus that causes COVID-19.

However, it remains unclear whether there is a reduced immune response to SARS-CoV-2 in these patients. There is a need to evaluate the antibody response in patients with diabetes following COVID-19 vaccination and the impact of glucose control on antibody response.

Methods & findings

This study included 161 adult patients with T1D or T2D and 86 healthy controls that received a COVID-19 vaccine (BioNTech/Pfizer, Moderna, or AstraZeneca). Patients belonged to one of four groups depending on the type of diabetes and HbA1c levels (average blood glucose over 2-3 months). Blood antibody levels were determined 7-14 days after the first vaccine and 14-21 days after the second vaccine.

Of 161 patients with diabetes, the results of 150 patients were analyzed. After the first vaccine, 52.7% of patients with T1D and 48% of patients with T2D had antibody levels above the cut-off for a positive result (0.8) using the Roche’s Elecsys anti-SARS-CoV-2 immunoassay. After the second vaccine, antibody levels were similar for patients with T1D, T2D, and healthy controls.

87.4% of study participants had injection site reactions after the first vaccine and 63.3% of participants after the second dose.

The bottom line

The study showed that patients with T1D and T2D had a similar antibody response to COVID-19 vaccines as healthy individuals.

The fine print

The study only investigated one aspect of the vaccine immune response, antibody levels. Most participants received an mRNA-based (Pfizer and Moderna) vaccine compared to the adenovirus-based (AstraZeneca) COVID-19 vaccine.

Published By :

Diabetes, Obesity and Metabolism

Date :

Jan 04, 2022

Original Title :

Humoral immune response to Covid-19 vaccination in diabetes: age-dependent but independent of type of diabetes and glycaemic control – the prospective COVAC-DM cohort study.

click here to get personalized updates